316 related articles for article (PubMed ID: 27838135)
1. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
[TBL] [Abstract][Full Text] [Related]
3. Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity.
Manders DB; Kehoe SM; Miller DS; Lea JS; Richardson DL
Am J Clin Oncol; 2018 Aug; 41(8):797-801. PubMed ID: 28225444
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
5. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand.
Boupaijit K; Suprasert P
Asian Pac J Cancer Prev; 2016; 17(3):1123-7. PubMed ID: 27039736
[TBL] [Abstract][Full Text] [Related]
9. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
Lorusso D; Petrelli F; Coinu A; Raspagliesi F; Barni S
Gynecol Oncol; 2014 Apr; 133(1):117-23. PubMed ID: 24486604
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Tinker AV; Fiorino L; O'Dwyer H; Kumar A
Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
Machida H; Moeini A; Ciccone MA; Mostofizadeh S; Takiuchi T; Brunette LL; Roman LD; Matsuo K
Am J Clin Oncol; 2018 Sep; 41(9):851-860. PubMed ID: 28763329
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
Tanigawa T; Matoda M; Yamamoto A; Nomura H; Okamoto S; Sakamoto K; Kondo E; Omatsu K; Kato K; Takeshima N
Arch Gynecol Obstet; 2016 Mar; 293(3):633-8. PubMed ID: 26305033
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.
Pectasides D; Fountzilas G; Papaxoinis G; Pectasides E; Xiros N; Sykiotis C; Koumarianou A; Psyrri A; Panayiotides J; Economopoulos T
Int J Gynecol Cancer; 2009 May; 19(4):777-81. PubMed ID: 19509587
[TBL] [Abstract][Full Text] [Related]
14. Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer.
Coronel J; Cetina L; Candelaria M; González-Fierro A; Arias D; Cantu D; Dueñas-González A
Med Oncol; 2009; 26(2):210-4. PubMed ID: 19016011
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.
Song M; DiPaola RS; Cracchiolo BM; Gibbon DG; Hellmann M; Nieves-Neira W; Vaidya A; Wagreich AR; Shih WJ; Rodriguez-Rodriguez L
Int J Gynecol Cancer; 2014 Nov; 24(9):1636-41. PubMed ID: 25304678
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
[TBL] [Abstract][Full Text] [Related]
19. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
